Pembrolizumab + Lenvatinib
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Melanoma, Uveal
Conditions
Melanoma, Uveal
Trial Timeline
Aug 2, 2022 → Jun 1, 2027
NCT ID
NCT05308901About Pembrolizumab + Lenvatinib
Pembrolizumab + Lenvatinib is a phase 2 stage product being developed by Eisai for Melanoma, Uveal. The current trial status is active. This product is registered under clinical trial identifier NCT05308901. Target conditions include Melanoma, Uveal.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05308901 | Phase 2 | Active |
| NCT05064280 | Phase 2 | Recruiting |
| NCT04704219 | Phase 2 | Completed |
| NCT03797326 | Phase 2 | Completed |
Competing Products
20 competing products in Melanoma, Uveal
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Binimetinib Oral Tablet | Biotrial | Phase 1 | 25 |
| Tasisulam-sodium + Paclitaxel | Eli Lilly | Phase 3 | 77 |
| [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT01 + [68Ga]VMT02 | Perspective Therapeutics | Phase 1 | 25 |
| FYB206 + Keytruda | Formycon AG | Phase 1 | 25 |
| PLX3397 | Daiichi Sankyo | Pre-clinical | 23 |
| PLX3397 + Pembrolizumab | Daiichi Sankyo | Phase 1/2 | 41 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DS-8273a + Nivolumab | Daiichi Sankyo | Phase 1 | 33 |
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| enfortumab vedotin + pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| YM155 | Astellas Pharma | Phase 2 | 52 |
| YM155 + Docetaxel | Astellas Pharma | Phase 2 | 52 |
| Denileukin diftitox | Eisai | Phase 2 | 52 |
| E7080 | Eisai | Phase 1 | 33 |
| lenvatinib + pembrolizumab | Eisai | Phase 2 | 52 |
| MORAb-004 (monoclonal antibody) | Eisai | Phase 2 | 52 |
| Lenvatinib + Lenvatinib + Dacarbazine | Eisai | Phase 1/2 | 41 |
| E7386 + Pembrolizumab + Lenvatinib | Eisai | Phase 1/2 | 41 |